https://br.sputniknews.com/americas/2021071517784610-covid-19-russia-aprovou-vacina-sputnik-v-produzida-na-argentina-anuncia-presidente-fernandez/
+39
JohninMK
Russian_Patriot_
dino00
ALAMO
Rasisuki Nebia
UZB-76
Arrow
Backman
lancelot
Big_Gazza
mnztr
Kiko
Nomad5891
lyle6
Scorpius
owais.usmani
PapaDragon
flamming_python
limb
Walther von Oldenburg
LMFS
GarryB
kvs
SeigSoloyvov
par far
Hole
calripson
PhSt
George1
Regular
miketheterrible
Project Canada
SKALA.Medica
higurashihougi
sepheronx
magnumcromagnon
AlfaT8
NationalRus
KomissarBojanchev
43 posters
Russian Medical Development: News
Kiko- Posts : 3435
Points : 3499
Join date : 2020-11-11
Age : 75
Location : Brasilia
- Post n°351
Re: Russian Medical Development: News
COVID-19: Russia approves Sputnik V vaccine produced in Argentina, President Fernández announces.
https://br.sputniknews.com/americas/2021071517784610-covid-19-russia-aprovou-vacina-sputnik-v-produzida-na-argentina-anuncia-presidente-fernandez/
https://br.sputniknews.com/americas/2021071517784610-covid-19-russia-aprovou-vacina-sputnik-v-produzida-na-argentina-anuncia-presidente-fernandez/
GarryB, Big_Gazza and kvs like this post
limb- Posts : 1550
Points : 1576
Join date : 2020-09-17
- Post n°352
Re: Russian Medical Development: News
The current opposition towards vaccines in Russia proves that the majority of the population both believes western propaganda, and believes that anything produced by russia must be inferior to western products. This proves that the majority of Russians are too retarded for their own goid.
The other rage enducing phenomenon is russians to think that its worth it to get infected. We see this cancerous macho mindset of thinking that because someone is gealthy that means they can weather the virus easily, but somehow are too cowardly to take a vaccine based on proven concepts and mich lower chance of side effects.
Now almost all people who are opposed to coronavirus vaccines is because of concerns for long term effects. However vaccinese by definition do not cause long term effects, because theyre not taken constantly. In fact there has never been any vaccine created that has caused side effects more than 8 weeks after vaccination.
This proves that in most countries, basic biological and medical education is severely lacking and the population is more susceptible to medical pseudoscience than financial scams.
The other rage enducing phenomenon is russians to think that its worth it to get infected. We see this cancerous macho mindset of thinking that because someone is gealthy that means they can weather the virus easily, but somehow are too cowardly to take a vaccine based on proven concepts and mich lower chance of side effects.
Now almost all people who are opposed to coronavirus vaccines is because of concerns for long term effects. However vaccinese by definition do not cause long term effects, because theyre not taken constantly. In fact there has never been any vaccine created that has caused side effects more than 8 weeks after vaccination.
This proves that in most countries, basic biological and medical education is severely lacking and the population is more susceptible to medical pseudoscience than financial scams.
PapaDragon likes this post
kvs- Posts : 15617
Points : 15754
Join date : 2014-09-11
Location : Turdope's Kanada
- Post n°353
Re: Russian Medical Development: News
It's called natural selection. This is why welfare enabling out-breeding by retards of more capable genetics is a bad thing.
For example, current bleeding heart laws created by beta simps give an incentive to welfare bum single mothers to have as
many children as possible. The support is not saving some poor child from poverty, it is creating more children living in
poverty.
For example, current bleeding heart laws created by beta simps give an incentive to welfare bum single mothers to have as
many children as possible. The support is not saving some poor child from poverty, it is creating more children living in
poverty.
GarryB likes this post
GarryB- Posts : 40006
Points : 40502
Join date : 2010-03-30
Location : New Zealand
- Post n°354
Re: Russian Medical Development: News
The current opposition towards vaccines in Russia proves that the majority of the population both believes western propaganda,
It proves nothing of the sort.
A bit of skepticism is actually quite healthy, but the way Covid is being reported the vast majority of people everywhere think it is something that kills old people and they are not too far wrong in that assumption.
When it does not effect them then they don't treat it with the respect they should be treating it with, we really don't know what damage it might do to any particular individual that gets it once let alone multiple times.
What will be the driving force for people choosing vaccination is their desire to get back to a normal life where they can go to bars and go out clubbing or simply go to their place of work and earn some money, or go on holiday.
There is freedom of choice of course but every choice has a consequence, so choosing not to be vaccinated will have serious and obvious impacts on your day to day life and try to buy a vaccination certificate and you might be buying it from an FSB agent... who may rip you off and give you something that is worthless, or they might start putting people in jail for that sort of stuff... either of which is fine by me.
They could earn a lot of money from these idiots... perhaps fund something useful with the money.
The support is not saving some poor child from poverty, it is creating more children living in
poverty.
Would correct that to say:
The support is not saving some poor child from poverty, it is creating more children trapped living in poverty.
ALAMO- Posts : 7232
Points : 7326
Join date : 2014-11-25
- Post n°355
Re: Russian Medical Development: News
I would hold your horses, lads, as the last check shows 1.2 mln people vaccinated daily.
They are above the world's average.
They are above the world's average.
dino00 likes this post
dino00- Posts : 1677
Points : 1714
Join date : 2012-10-12
Age : 36
Location : portugal
- Post n°356
Re: Russian Medical Development: News
ALAMO wrote:I would hold your horses, lads, as the last check shows 1.2 mln people vaccinated daily.
They are above the world's average.
Can you put a source?
flamming_python- Posts : 9368
Points : 9430
Join date : 2012-01-30
- Post n°357
Re: Russian Medical Development: News
dino00 wrote:ALAMO wrote:I would hold your horses, lads, as the last check shows 1.2 mln people vaccinated daily.
They are above the world's average.
Can you put a source?
15th July - 20.92% of the population have received at least one dose
16th July - 21.76% of the population have received at least one dose
https://index.minfin.com.ua/reference/coronavirus/vaccination/russia/
21.76 - 20.92 = 0.84
0.84% of Russia's population (146.2 mil) is 1.228 million
Although the average pace of vaccination is slower
Big_Gazza likes this post
Kiko- Posts : 3435
Points : 3499
Join date : 2020-11-11
Age : 75
Location : Brasilia
- Post n°358
Re: Russian Medical Development: News
Chile approves emergency use of Sputnik V vaccine, 21.07.2021.
https://mundo.sputniknews.com/20210721/chile-aprueba-el-uso-de-emergencia-de-la-vacuna-rusa-sputnik-v-1114355972.html
https://mundo.sputniknews.com/20210721/chile-aprueba-el-uso-de-emergencia-de-la-vacuna-rusa-sputnik-v-1114355972.html
dino00 likes this post
kvs- Posts : 15617
Points : 15754
Join date : 2014-09-11
Location : Turdope's Kanada
- Post n°359
Re: Russian Medical Development: News
In "freedom country" Canada we no longer have the choice of even the AstraZeneca vaccine. It is all mRNA GMO experimentation
with Pfizer and Moderna. If the long term damage from these GMO concoctions is confirmed this will be one of the biggest crimes
against humanity in history.
with Pfizer and Moderna. If the long term damage from these GMO concoctions is confirmed this will be one of the biggest crimes
against humanity in history.
miketheterrible likes this post
miketheterrible- Posts : 7383
Points : 7341
Join date : 2016-11-06
- Post n°360
Re: Russian Medical Development: News
kvs wrote:In "freedom country" Canada we no longer have the choice of even the AstraZeneca vaccine. It is all mRNA GMO experimentation
with Pfizer and Moderna. If the long term damage from these GMO concoctions is confirmed this will be one of the biggest crimes
against humanity in history.
Well, you and I could file a class action lawsuite if it ever comes to it.
GarryB likes this post
Scorpius- Posts : 1532
Points : 1532
Join date : 2020-11-06
Age : 36
- Post n°361
Re: Russian Medical Development: News
according to the Russian customs, the export of vaccines from Russia (over $300 million) for the first 5 months doubled the total value for the previous 3 years. Compared to the same period in 2020, the growth was 3,180%.
https://forbes-ru.turbopages.org/forbes.ru/s/newsroom/biznes/436571-rossiya-eksportirovala-v-32-raza-bolshe-vakcin-dlya-lyudey-v-2021-godu
https://forbes-ru.turbopages.org/forbes.ru/s/newsroom/biznes/436571-rossiya-eksportirovala-v-32-raza-bolshe-vakcin-dlya-lyudey-v-2021-godu
GarryB, Big_Gazza, miketheterrible and Hole like this post
flamming_python- Posts : 9368
Points : 9430
Join date : 2012-01-30
- Post n°362
Re: Russian Medical Development: News
Scorpius wrote:according to the Russian customs, the export of vaccines from Russia (over $300 million) for the first 5 months doubled the total value for the previous 3 years. Compared to the same period in 2020, the growth was 3,180%.
https://forbes-ru.turbopages.org/forbes.ru/s/newsroom/biznes/436571-rossiya-eksportirovala-v-32-raza-bolshe-vakcin-dlya-lyudey-v-2021-godu
At once joyous and sad
Sad that so much profit should have been made off a vaccine vital for humanity at the moment
Although it doesn't specify the actual amount of profit, rather the revenue.
GarryB likes this post
Russian_Patriot_- Posts : 1286
Points : 1300
Join date : 2021-06-08
- Post n°363
Re: Russian Medical Development: News
GarryB, flamming_python and Big_Gazza like this post
GarryB- Posts : 40006
Points : 40502
Join date : 2010-03-30
Location : New Zealand
- Post n°364
Re: Russian Medical Development: News
At once joyous and sad
Sad that so much profit should have been made off a vaccine vital for humanity at the moment
Although it doesn't specify the actual amount of profit, rather the revenue.
I rather suspect the figures for western pharma companies would be in the tens of billions if not trillions and they would have no shame in offering 10000% price markups during pandemics.
I rather suspect it is total revenue and that their profits were nothing like those of the west because they are dealing with countries that simply can't afford to spend a lot of money on such things.
The companies you should worry about are the ones that demand waivers from fault or injury and refuse to give figures about price and cost.
Kiko- Posts : 3435
Points : 3499
Join date : 2020-11-11
Age : 75
Location : Brasilia
- Post n°365
Re: Russian Medical Development: News
Skvortsova spoke about the study of the drug against coronavirus "Mir-19", 23.08.2021.
Head of FMBA Skvortsova: report on the study of the drug against coronavirus "Mir-19" will be presented in September.
MOSCOW, 23 Aug - RIA Novosti. The second phase of clinical trials of a Russian drug for coronavirus is ending, said Veronika Skvortsova , head of the Federal Biomedical Agency.
“About 160 patients have already received Mir-19. We plan to submit a report to the Ministry of Health sometime in September and then resolve the issue of its registration,” she said on the air of the Russia 24 channel.
It is known about "Mir-19" that it is an etiotropic drug, in fact, an antidote against a virus. It consists of two components - small interfering RNAs, which should prevent SARS-CoV-2 from multiplying, and a carrier peptide. According to the developers, it does not affect the human genome.
Earlier it was reported that the creation of a medicine is a technically more difficult task than the development of a vaccine: in addition to the selection of a substance, it is necessary to calculate its concentration and dose. There is a consensus in the professional community that preventive vaccinations are more effective than treatment.
https://ria.ru/20210823/koronavirus-1746846946.html
Head of FMBA Skvortsova: report on the study of the drug against coronavirus "Mir-19" will be presented in September.
MOSCOW, 23 Aug - RIA Novosti. The second phase of clinical trials of a Russian drug for coronavirus is ending, said Veronika Skvortsova , head of the Federal Biomedical Agency.
“About 160 patients have already received Mir-19. We plan to submit a report to the Ministry of Health sometime in September and then resolve the issue of its registration,” she said on the air of the Russia 24 channel.
It is known about "Mir-19" that it is an etiotropic drug, in fact, an antidote against a virus. It consists of two components - small interfering RNAs, which should prevent SARS-CoV-2 from multiplying, and a carrier peptide. According to the developers, it does not affect the human genome.
Earlier it was reported that the creation of a medicine is a technically more difficult task than the development of a vaccine: in addition to the selection of a substance, it is necessary to calculate its concentration and dose. There is a consensus in the professional community that preventive vaccinations are more effective than treatment.
https://ria.ru/20210823/koronavirus-1746846946.html
GarryB, flamming_python and kvs like this post
Russian_Patriot_- Posts : 1286
Points : 1300
Join date : 2021-06-08
- Post n°366
Re: Russian Medical Development: News
Technodinamika to launch mobile paramedic and midwifery centers.
Technodinamika Holding of Rostec State Corporation has signed a bilateral cooperation agreement with Interautocenter for the production of mobile health centers-paramedic and midwifery centers-within the framework of the Army-2021 International Military-Technical Forum. NPO Splav named after A. N. Ganichev will be engaged in completing ambulances.
Paramedic and midwifery centers (FAP) will be formed on the basis of GAZ vehicles. Mobile health centers are planned to be delivered to all regions of Russia within the framework of the national project "Healthcare".
"Each vehicle will be equipped with all the necessary equipment for the examination and treatment of patients on the ground, as well as for vaccination. In other words, we will get a kind of "polyclinic on wheels", which will be able to serve several localities at once. Moreover, due to the high cross – country ability of the car, medical care is possible in the most inaccessible places" – Igor Nasenkov, General Director of Technodinamika Holding said.
"We already have experience in assembling such medical complexes. Since 2019, NPO Splav has been an aggregator and supplier of ambulances under the program of updating the ambulance fleet in the regions of Russia. The company is engaged in completing vehicles with Russian-made medical equipment" – Vladimir Kondaurov, Deputy General Director for Civil Products of JSC NPO Splav named after A. N. Ganichev said.
Vehicle assembly is carried out jointly with the partner company on the certified site of the enterprise. Here, cars are also equipped with medical equipment. The fleet of cars is formed on the basis of the Gazelle-Business and Gazelle-NEXT chassis, and for regions with hard – to-reach settlements-on the basis of GAZ Sobol.
Also, within the framework of the Army-2021 military-technical forum, Splav NGO presented new medical devices-LifeStream HEPAR and LifeStream ECMO complexes, which allow resuscitating patients with sudden cardiac arrest and pulmonary insufficiency, restoring and maintaining the viability of transplants both in the donor patient's body and outside the body. There are no analogues of such equipment in Russia today.
The work is carried out jointly with the Central Research and Development Institute of Robotics and Technical Cybernetics of St. Petersburg. The medical co-executor of the project is the First Saint Petersburg State University named after Academician I. P. Pavlov.
One of the perfusion complexes developed as part of the project – LifeStream ECMO – is designed to maintain artificial blood circulation in the patient's body during cardiac arrest, blood oxygen saturation (oxygenation) during the development of acute respiratory failure for subsequent transportation of the patient to the hospital, intensive care unit and intensive care unit. The implementation of this project will reduce mortality from acute respiratory failure and sudden cardiac arrest.
"The device can be successfully used for extracorporeal support of patients in critical condition with acute respiratory or heart failure caused by COVID-19. Its effectiveness has already been proven in an experiment on animals simulating sudden cardiac arrest. At the moment, the device is undergoing state registration" – Alexander Smirnov, General Director of the Ganichev Splav NGO said.
Another development – the LifeStream HEPAR complex is able to solve one of the main problems of transplantology-the shortage of donor organs. Perfusion devices currently available on the transplantology market provide preservation and prolongation of organ storage under low temperature conditions. This approach is justified only when working with donor organs of perfect quality. The perfusion complex "Alloy" is able to restore damaged donor organs (liver), as well as assess the functional state of the organ, transport and treatment.
Source:
![Russian Medical Development: News - Page 15 Img_2185](https://i.servimg.com/u/f81/20/34/63/61/img_2185.jpg)
Technodinamika Holding of Rostec State Corporation has signed a bilateral cooperation agreement with Interautocenter for the production of mobile health centers-paramedic and midwifery centers-within the framework of the Army-2021 International Military-Technical Forum. NPO Splav named after A. N. Ganichev will be engaged in completing ambulances.
Paramedic and midwifery centers (FAP) will be formed on the basis of GAZ vehicles. Mobile health centers are planned to be delivered to all regions of Russia within the framework of the national project "Healthcare".
"Each vehicle will be equipped with all the necessary equipment for the examination and treatment of patients on the ground, as well as for vaccination. In other words, we will get a kind of "polyclinic on wheels", which will be able to serve several localities at once. Moreover, due to the high cross – country ability of the car, medical care is possible in the most inaccessible places" – Igor Nasenkov, General Director of Technodinamika Holding said.
"We already have experience in assembling such medical complexes. Since 2019, NPO Splav has been an aggregator and supplier of ambulances under the program of updating the ambulance fleet in the regions of Russia. The company is engaged in completing vehicles with Russian-made medical equipment" – Vladimir Kondaurov, Deputy General Director for Civil Products of JSC NPO Splav named after A. N. Ganichev said.
Vehicle assembly is carried out jointly with the partner company on the certified site of the enterprise. Here, cars are also equipped with medical equipment. The fleet of cars is formed on the basis of the Gazelle-Business and Gazelle-NEXT chassis, and for regions with hard – to-reach settlements-on the basis of GAZ Sobol.
Also, within the framework of the Army-2021 military-technical forum, Splav NGO presented new medical devices-LifeStream HEPAR and LifeStream ECMO complexes, which allow resuscitating patients with sudden cardiac arrest and pulmonary insufficiency, restoring and maintaining the viability of transplants both in the donor patient's body and outside the body. There are no analogues of such equipment in Russia today.
The work is carried out jointly with the Central Research and Development Institute of Robotics and Technical Cybernetics of St. Petersburg. The medical co-executor of the project is the First Saint Petersburg State University named after Academician I. P. Pavlov.
One of the perfusion complexes developed as part of the project – LifeStream ECMO – is designed to maintain artificial blood circulation in the patient's body during cardiac arrest, blood oxygen saturation (oxygenation) during the development of acute respiratory failure for subsequent transportation of the patient to the hospital, intensive care unit and intensive care unit. The implementation of this project will reduce mortality from acute respiratory failure and sudden cardiac arrest.
"The device can be successfully used for extracorporeal support of patients in critical condition with acute respiratory or heart failure caused by COVID-19. Its effectiveness has already been proven in an experiment on animals simulating sudden cardiac arrest. At the moment, the device is undergoing state registration" – Alexander Smirnov, General Director of the Ganichev Splav NGO said.
Another development – the LifeStream HEPAR complex is able to solve one of the main problems of transplantology-the shortage of donor organs. Perfusion devices currently available on the transplantology market provide preservation and prolongation of organ storage under low temperature conditions. This approach is justified only when working with donor organs of perfect quality. The perfusion complex "Alloy" is able to restore damaged donor organs (liver), as well as assess the functional state of the organ, transport and treatment.
Source:
![Russian Medical Development: News - Page 15 Img_2185](https://i.servimg.com/u/f81/20/34/63/61/img_2185.jpg)
Kiko- Posts : 3435
Points : 3499
Join date : 2020-11-11
Age : 75
Location : Brasilia
- Post n°367
Re: Russian Medical Development: News
"We do not expect serious side effects": Director of the Institute of Immunology - on the drug for the treatment of coronavirus "MIR-19", by Ekaterina Kiyko for RT Rússia. 01/09/2021.
In Russia, the second stage of clinical trials of the drug for the treatment of coronavirus "MIR-19" is coming to an end. Musa Khaitov, director of the Institute of Immunology of the Federal Medical and Biological Agency of Russia, spoke about this in an interview with RT. According to him, during the first two stages of the study, the safety of the drug was demonstrated. Experts expect that MIR-19 will be intended for patients of all ages. The immunologist added that work is now underway to create an industrial technology for the production of the drug, so that after registration it will be available to as many Russians as possible.
What is the mechanism of action of the drug "MIR-19"? What are its main characteristics?
"MIR-19" is a unique etiotropic antiviral drug that acts directly on the SARS-CoV-2 virus that causes COVID-19. It was created in such a way that its active component is the so-called small interfering RNAs. Therefore, the drug is called "MIR-19", this is an abbreviation ... This RNA is aimed at a certain conserved part of the genome of the SARS-CoV-2 virus, which, after interaction, undergoes certain modifications and thus is effectively removed from the infected cell.
The main entrance gate of infection is the upper respiratory tract. The virus multiplies in the epithelium of the upper and lower respiratory tract. We need to suppress its reproduction. Therefore, inhalation was tested and it was proved that this is the most effective way of delivering the drug and so it will be able to most effectively implement its antiviral activity.
Why have no effective drugs against coronavirus been created in the world until today?
The fact is that the creation of a drug is a very long process. You need to understand that this takes years, and maybe decades. A little more than a year and a half has passed since the beginning of the epidemic. And accordingly, the leading scientific teams of the world began to develop drugs against SARS-CoV-2 almost a year and a half ago. Therefore, today a very large number of candidate drugs are at various stages of development all over the world.
With the drug "MIR-19" in just over a year and a half we managed to go through this very difficult path: from the idea of developing the drug itself to the second phase of clinical trials. This became possible thanks to the colossal work of our team at the Institute of Immunology, as well as our partners - the St. Petersburg Institute of Vaccines and Serums.
Have you already published an article about the effectiveness of your drug in international peer-reviewed journals? Are you planning any other publications on the efficacy, safety of the drug and the last stage of trials?
In April of this year, we published an article in Allergy magazine. It is by far the world's leading journal of clinical immunology. In it, for the first time in the world, we demonstrated the possibility of creating an antiviral drug against SARS-CoV-2 based on small interfering RNAs. Of course, after the completion of the second phase of clinical trials and registration of the drug, we will publish the data in a serious international scientific publication.
Does the drug "MIR-19" have analogues?
There are no registered analogues. The drug is absolutely unique.
In your last interview with RT, you mentioned that the drug is absolutely safe. To date, have not been identified any side effects? Will the drug be indicated for all age groups?
The drug has gone through a full cycle of preclinical studies, where it was demonstrated that it is safe and belongs to the class of low-toxic compounds. Based on this, we received permission from the Ministry of Health to conduct the first phase of clinical trials, where safety is checked in healthy volunteers. The safety of the drug has been confirmed.
Today we are conducting the second phase of clinical trials, where its safety will be confirmed already in patients with coronavirus. Considering the mechanism of action of the drug and the results that we received during preclinical studies and in the first phase, we do not expect any serious side effects from it. I would very much like to hope that it will be available to both elderly patients and the smallest children.
Will MIR-19 be used only for the treatment of COVID-19? Or will it be able to form immunity against coronavirus infection, like a vaccine?
The fact is that MIR-19 is a drug, that is, it is not capable of forming immunity, like vaccines. It can lead to a decrease in viral load in a person who has contracted the coronavirus. Accordingly, a person recovers much faster by taking this drug.
In September, you are going to submit documents to the Ministry of Health for registration of the drug. Do you currently have a project for the production of the first doses of the drug, how much do you plan to release?
The second phase of clinical trials of the drug is now coming to an end. After submitting the report to the regulator, we will initiate the registration procedure. First of all, the drug will be available in hospitals, that is, those patients who need it most. Now we are very actively working on scaling up, on creating industrial technology, so that in the future the drug, of course, will be available to all segments of the population.
Are there already requests for the use of the drug "MIR-19" from foreign countries?
Yes, there is interest. In particular, representatives of pharmaceutical companies from Japan and South Korea contacted me with letters. It is planned to export the drug to other countries. I would like to help as many people as possible who can potentially get coronavirus.
https://russian.rt.com/science/article/901631-lekarstvo-koronavirus-mir-19-fmba
In Russia, the second stage of clinical trials of the drug for the treatment of coronavirus "MIR-19" is coming to an end. Musa Khaitov, director of the Institute of Immunology of the Federal Medical and Biological Agency of Russia, spoke about this in an interview with RT. According to him, during the first two stages of the study, the safety of the drug was demonstrated. Experts expect that MIR-19 will be intended for patients of all ages. The immunologist added that work is now underway to create an industrial technology for the production of the drug, so that after registration it will be available to as many Russians as possible.
What is the mechanism of action of the drug "MIR-19"? What are its main characteristics?
"MIR-19" is a unique etiotropic antiviral drug that acts directly on the SARS-CoV-2 virus that causes COVID-19. It was created in such a way that its active component is the so-called small interfering RNAs. Therefore, the drug is called "MIR-19", this is an abbreviation ... This RNA is aimed at a certain conserved part of the genome of the SARS-CoV-2 virus, which, after interaction, undergoes certain modifications and thus is effectively removed from the infected cell.
The main entrance gate of infection is the upper respiratory tract. The virus multiplies in the epithelium of the upper and lower respiratory tract. We need to suppress its reproduction. Therefore, inhalation was tested and it was proved that this is the most effective way of delivering the drug and so it will be able to most effectively implement its antiviral activity.
Why have no effective drugs against coronavirus been created in the world until today?
The fact is that the creation of a drug is a very long process. You need to understand that this takes years, and maybe decades. A little more than a year and a half has passed since the beginning of the epidemic. And accordingly, the leading scientific teams of the world began to develop drugs against SARS-CoV-2 almost a year and a half ago. Therefore, today a very large number of candidate drugs are at various stages of development all over the world.
With the drug "MIR-19" in just over a year and a half we managed to go through this very difficult path: from the idea of developing the drug itself to the second phase of clinical trials. This became possible thanks to the colossal work of our team at the Institute of Immunology, as well as our partners - the St. Petersburg Institute of Vaccines and Serums.
Have you already published an article about the effectiveness of your drug in international peer-reviewed journals? Are you planning any other publications on the efficacy, safety of the drug and the last stage of trials?
In April of this year, we published an article in Allergy magazine. It is by far the world's leading journal of clinical immunology. In it, for the first time in the world, we demonstrated the possibility of creating an antiviral drug against SARS-CoV-2 based on small interfering RNAs. Of course, after the completion of the second phase of clinical trials and registration of the drug, we will publish the data in a serious international scientific publication.
Does the drug "MIR-19" have analogues?
There are no registered analogues. The drug is absolutely unique.
In your last interview with RT, you mentioned that the drug is absolutely safe. To date, have not been identified any side effects? Will the drug be indicated for all age groups?
The drug has gone through a full cycle of preclinical studies, where it was demonstrated that it is safe and belongs to the class of low-toxic compounds. Based on this, we received permission from the Ministry of Health to conduct the first phase of clinical trials, where safety is checked in healthy volunteers. The safety of the drug has been confirmed.
Today we are conducting the second phase of clinical trials, where its safety will be confirmed already in patients with coronavirus. Considering the mechanism of action of the drug and the results that we received during preclinical studies and in the first phase, we do not expect any serious side effects from it. I would very much like to hope that it will be available to both elderly patients and the smallest children.
Will MIR-19 be used only for the treatment of COVID-19? Or will it be able to form immunity against coronavirus infection, like a vaccine?
The fact is that MIR-19 is a drug, that is, it is not capable of forming immunity, like vaccines. It can lead to a decrease in viral load in a person who has contracted the coronavirus. Accordingly, a person recovers much faster by taking this drug.
In September, you are going to submit documents to the Ministry of Health for registration of the drug. Do you currently have a project for the production of the first doses of the drug, how much do you plan to release?
The second phase of clinical trials of the drug is now coming to an end. After submitting the report to the regulator, we will initiate the registration procedure. First of all, the drug will be available in hospitals, that is, those patients who need it most. Now we are very actively working on scaling up, on creating industrial technology, so that in the future the drug, of course, will be available to all segments of the population.
Are there already requests for the use of the drug "MIR-19" from foreign countries?
Yes, there is interest. In particular, representatives of pharmaceutical companies from Japan and South Korea contacted me with letters. It is planned to export the drug to other countries. I would like to help as many people as possible who can potentially get coronavirus.
https://russian.rt.com/science/article/901631-lekarstvo-koronavirus-mir-19-fmba
GarryB, kvs, Hole and Russian_Patriot_ like this post
Kiko- Posts : 3435
Points : 3499
Join date : 2020-11-11
Age : 75
Location : Brasilia
- Post n°368
Re: Russian Medical Development: News
Russian health agency expects to apply for registration of its anticovid drug MIR-19 this year, 29/09/2021.
MOSCOW (Sputnik)-The Federal Medical and Biological Agency of Russia (FMBA) expects to submit the registration documents of its coronavirus drug MIR-19 during the current year, said the head of the agency, Veronika Skvortsova.
"We hope that this year the second phase will be completed and the report of the second phase will make it possible to register this drug so that it can be widely used in medical practice," Skvortsova told the press.
She noted that the agency plans to conduct the third phase of testing in parallel.
MIR-19, based on microRNAs, blocks specific components of the virus RNA and those responsible for copying them, so-called RNA polymerases.
Yandex Translate from Spanish.
https://mundo.sputniknews.com/20210930/agencia-rusa-de-salud-espera-solicitar-registro-de-su-farmaco-anticovid-mir-19-este-ano-1116593022.html
MOSCOW (Sputnik)-The Federal Medical and Biological Agency of Russia (FMBA) expects to submit the registration documents of its coronavirus drug MIR-19 during the current year, said the head of the agency, Veronika Skvortsova.
"We hope that this year the second phase will be completed and the report of the second phase will make it possible to register this drug so that it can be widely used in medical practice," Skvortsova told the press.
She noted that the agency plans to conduct the third phase of testing in parallel.
MIR-19, based on microRNAs, blocks specific components of the virus RNA and those responsible for copying them, so-called RNA polymerases.
Yandex Translate from Spanish.
https://mundo.sputniknews.com/20210930/agencia-rusa-de-salud-espera-solicitar-registro-de-su-farmaco-anticovid-mir-19-este-ano-1116593022.html
GarryB, kvs, Hole and Russian_Patriot_ like this post
Kiko- Posts : 3435
Points : 3499
Join date : 2020-11-11
Age : 75
Location : Brasilia
- Post n°369
Re: Russian Medical Development: News
Murashko announced the removal of barriers to the recognition of "Sputnik V" in WHO
Head of the Ministry of Health Murashko: all barriers to the recognition of the Sputnik V vaccine in WHO have been removed.
GENEVA, October 2 - RIA Novosti, Elizaveta Isakova. All barriers to the recognition of the Sputnik V vaccine in WHO have been removed, and some administrative procedures remain, Health Minister Mikhail Murashko told reporters following a meeting with US officials in Geneva.
" Russia's position on the registration and promotion of the Russian Sputnik V vaccine has been fully heard. <...> Now it is necessary that the company that registers the vaccine at the WHO site sign a number of documents and provide additional papers," he said.
According to the minister, the general director of the organization, Tedros Ghebreyesus, confirmed that there are no obstacles for "further work". They met yesterday.
Murashko also added that the United States is interested in mutual recognition of vaccination certificates and that progress can be expected in this direction.
There are now five COVID-19 vaccines registered in the country. The first of them, Sputnik V, created by the Gamaleya National Research Center for Epidemiology and Microbiology with the support of the RDIF , is widely used for mass immunization, and has been approved in 70 countries. Russians also have access to "EpiVacCorona" from the Novosibirsk center "Vector" and "KoviVak" from the Chumakov Center of the Russian Academy of Sciences .
For revaccination, Sputnik Light is recommended - a light version of Sputnik V, which assumes a single injection of the drug. In addition, the Ministry of Health recently registered EpiVacKoron-N - it contains the same active ingredient as in EpiVacKoron, but they are synthesized in different ways.
In July, the regulator also issued a permit for clinical trials of the drug to the St. Petersburg Research Institute of Vaccines and Serums of the Federal Biomedical Agency.
https://ria.ru/20211002/murashko-1752797805.html
Head of the Ministry of Health Murashko: all barriers to the recognition of the Sputnik V vaccine in WHO have been removed.
GENEVA, October 2 - RIA Novosti, Elizaveta Isakova. All barriers to the recognition of the Sputnik V vaccine in WHO have been removed, and some administrative procedures remain, Health Minister Mikhail Murashko told reporters following a meeting with US officials in Geneva.
" Russia's position on the registration and promotion of the Russian Sputnik V vaccine has been fully heard. <...> Now it is necessary that the company that registers the vaccine at the WHO site sign a number of documents and provide additional papers," he said.
According to the minister, the general director of the organization, Tedros Ghebreyesus, confirmed that there are no obstacles for "further work". They met yesterday.
Murashko also added that the United States is interested in mutual recognition of vaccination certificates and that progress can be expected in this direction.
There are now five COVID-19 vaccines registered in the country. The first of them, Sputnik V, created by the Gamaleya National Research Center for Epidemiology and Microbiology with the support of the RDIF , is widely used for mass immunization, and has been approved in 70 countries. Russians also have access to "EpiVacCorona" from the Novosibirsk center "Vector" and "KoviVak" from the Chumakov Center of the Russian Academy of Sciences .
For revaccination, Sputnik Light is recommended - a light version of Sputnik V, which assumes a single injection of the drug. In addition, the Ministry of Health recently registered EpiVacKoron-N - it contains the same active ingredient as in EpiVacKoron, but they are synthesized in different ways.
In July, the regulator also issued a permit for clinical trials of the drug to the St. Petersburg Research Institute of Vaccines and Serums of the Federal Biomedical Agency.
https://ria.ru/20211002/murashko-1752797805.html
kvs- Posts : 15617
Points : 15754
Join date : 2014-09-11
Location : Turdope's Kanada
- Post n°370
Re: Russian Medical Development: News
The WHO is like WADA. A NATzO dominated clown outfit. It has approved the unproven for long term safety mRNA lipid nanoparticle
vector GMO "vaccines" as soon as possible but has been dragging its scummy heels on Sputnik V. Sputnik V is manifestly safer than
the mRNA wonders with statistics accumulated around the world and especially with the absence of the ridiculous action of the mRNA
"vaccines". Expect a wave of cancers in a few years from these rubber stamped concoctions sold with brazen lies.
vector GMO "vaccines" as soon as possible but has been dragging its scummy heels on Sputnik V. Sputnik V is manifestly safer than
the mRNA wonders with statistics accumulated around the world and especially with the absence of the ridiculous action of the mRNA
"vaccines". Expect a wave of cancers in a few years from these rubber stamped concoctions sold with brazen lies.
GarryB, Big_Gazza, miketheterrible and Kiko like this post
Kiko- Posts : 3435
Points : 3499
Join date : 2020-11-11
Age : 75
Location : Brasilia
- Post n°371
Re: Russian Medical Development: News
Russia hopes that politics will not prevail in the issue of recognition of "Sputnik V" in the EU, 02/10/2021.
Deputy Foreign Minister of the Russian Federation Alexander Grushko believes that the Russian vaccine is recognized.
MOSCOW, October 2. / TASS /. The Russian Foreign Ministry expects that in the EU, when considering the issue of recognizing Russian vaccines, not political considerations will prevail, but economic arguments and a desire to make life easier for European citizens. This was announced to journalists on Saturday by the deputy head of the department, Alexander Grushko.
“It [the Russian vaccine] will be recognized, the process is not easy, but it has not stopped. We proceed from the fact that in the end, not political considerations will prevail, but competition, the need to unite efforts in the fight against this disease. The most important thing is to make people's lives easier. who need to cross borders, work, and in this sense we expect that the process will end with the certification of our vaccines - within the framework of WHO and EMA (European Medicines Agency - TASS) - by the relevant EU agencies, "he said.
Sputnik V has not yet received EMA approval for use in the European Union. With regard to this Russian vaccine, the position of the European Commission has remained unchanged since the start of the EU covid certification system in early July. The vaccine was registered in Russia on August 11, 2020, becoming the world's first officially registered drug for coronavirus.
Earlier, the head of the Ministry of Health of the Russian Federation, Mikhail Murashko, said that all barriers that prevented the registration of the Russian vaccine against the Sputnik V coronavirus with the World Health Organization had been removed.
https://tass.ru/politika/12563213
Deputy Foreign Minister of the Russian Federation Alexander Grushko believes that the Russian vaccine is recognized.
MOSCOW, October 2. / TASS /. The Russian Foreign Ministry expects that in the EU, when considering the issue of recognizing Russian vaccines, not political considerations will prevail, but economic arguments and a desire to make life easier for European citizens. This was announced to journalists on Saturday by the deputy head of the department, Alexander Grushko.
“It [the Russian vaccine] will be recognized, the process is not easy, but it has not stopped. We proceed from the fact that in the end, not political considerations will prevail, but competition, the need to unite efforts in the fight against this disease. The most important thing is to make people's lives easier. who need to cross borders, work, and in this sense we expect that the process will end with the certification of our vaccines - within the framework of WHO and EMA (European Medicines Agency - TASS) - by the relevant EU agencies, "he said.
Sputnik V has not yet received EMA approval for use in the European Union. With regard to this Russian vaccine, the position of the European Commission has remained unchanged since the start of the EU covid certification system in early July. The vaccine was registered in Russia on August 11, 2020, becoming the world's first officially registered drug for coronavirus.
Earlier, the head of the Ministry of Health of the Russian Federation, Mikhail Murashko, said that all barriers that prevented the registration of the Russian vaccine against the Sputnik V coronavirus with the World Health Organization had been removed.
https://tass.ru/politika/12563213
Kiko- Posts : 3435
Points : 3499
Join date : 2020-11-11
Age : 75
Location : Brasilia
- Post n°372
Re: Russian Medical Development: News
Moscow: Europe reaches the stage of continuous evaluation of Sputnik V, by Yulia Zvantsova for fr.sputnik. 09/10/2021.
The European Medicines Agency (EMA), which was submitted the Russian COVID vaccine Sputnik V in March, has "made great progress" in the procedure, the Russian foreign Minister announced, while the Ministry of Health has raised the possibility of a visit by inspectors of the European structure to Russia.
Work on the registration of the Russian anti-COVID vaccine Sputnik V by the European Medicines Agency is progressing well, said Russian Foreign Minister Sergey Lavrov.
"We are cooperating with the European Medicines Agency to register Sputnik V and we have made great progress. We are currently at the so-called continuous evaluation stage," he said at a meeting with members of the Association of European business in Russia.
But it is important that instead of hindering dialogue, politicians contribute to it, he stressed.
"We need to solve all these problems, those of registration and mutual recognition of vaccines, on the basis of a professional dialogue between epidemiologists and experts in the health and health sector. Politicians, for their part, must not prevent but, on the contrary, encourage by all means this professional dialogue," he concluded.
The EMA began the ongoing review of Sputnik V on 4 March 2021.
The EMA has the required documents since September
The documents for the approval of the Russian vaccine required by the EMA were transmitted to him in September, recalled this Friday the press service of the Russian Ministry of Health.
"Following bilateral consultations on the mutual recognition of vaccination certificates, the Ministry collected the necessary documents requested by the European side. They were sent to the EU representation in September. On the 30th of the month, an employee of the representation confirmed that he received them," the press service of the ministry noted.
At present, the two sides are working on organizing a visit by EMA inspectors as part of the Sputnik V certification procedure. The trip could take place in December, the ministry added.
"All obstacles are removed"
Russian Health Minister Mikhail Murashko had earlier visited Geneva and held talks with WHO Director-General Tedros Adhanom Ghebreyesus. He said at the end of the meeting that all obstacles to registering the vaccine with the WHO had been removed and that only a few documents had to be completed.
Tedros Adhanom Ghebreyesus subsequently posted a message on his Twitter account to thank his interlocutor and took care to write the word "thank you" in Russian.
Thank you, Russian Minister of Health Mikhail Murashko, for your visit and constructive meeting.
Yandex Translate from French.
https://fr.sputniknews.com/20211009/moscou-leurope-arrive-a-letape-devaluation-en-continu-du-spoutnik-v-1052063960.html
The European Medicines Agency (EMA), which was submitted the Russian COVID vaccine Sputnik V in March, has "made great progress" in the procedure, the Russian foreign Minister announced, while the Ministry of Health has raised the possibility of a visit by inspectors of the European structure to Russia.
Work on the registration of the Russian anti-COVID vaccine Sputnik V by the European Medicines Agency is progressing well, said Russian Foreign Minister Sergey Lavrov.
"We are cooperating with the European Medicines Agency to register Sputnik V and we have made great progress. We are currently at the so-called continuous evaluation stage," he said at a meeting with members of the Association of European business in Russia.
But it is important that instead of hindering dialogue, politicians contribute to it, he stressed.
"We need to solve all these problems, those of registration and mutual recognition of vaccines, on the basis of a professional dialogue between epidemiologists and experts in the health and health sector. Politicians, for their part, must not prevent but, on the contrary, encourage by all means this professional dialogue," he concluded.
The EMA began the ongoing review of Sputnik V on 4 March 2021.
The EMA has the required documents since September
The documents for the approval of the Russian vaccine required by the EMA were transmitted to him in September, recalled this Friday the press service of the Russian Ministry of Health.
"Following bilateral consultations on the mutual recognition of vaccination certificates, the Ministry collected the necessary documents requested by the European side. They were sent to the EU representation in September. On the 30th of the month, an employee of the representation confirmed that he received them," the press service of the ministry noted.
At present, the two sides are working on organizing a visit by EMA inspectors as part of the Sputnik V certification procedure. The trip could take place in December, the ministry added.
"All obstacles are removed"
Russian Health Minister Mikhail Murashko had earlier visited Geneva and held talks with WHO Director-General Tedros Adhanom Ghebreyesus. He said at the end of the meeting that all obstacles to registering the vaccine with the WHO had been removed and that only a few documents had to be completed.
Tedros Adhanom Ghebreyesus subsequently posted a message on his Twitter account to thank his interlocutor and took care to write the word "thank you" in Russian.
Thank you, Russian Minister of Health Mikhail Murashko, for your visit and constructive meeting.
Yandex Translate from French.
https://fr.sputniknews.com/20211009/moscou-leurope-arrive-a-letape-devaluation-en-continu-du-spoutnik-v-1052063960.html
GarryB- Posts : 40006
Points : 40502
Join date : 2010-03-30
Location : New Zealand
- Post n°373
Re: Russian Medical Development: News
Whether it is gas for energy for industry and to keep houses warm or vaccines... why does Russia have to try so hard to provide products to the EU.... why does the EU make it so hard for Russia to sell them cheap gas and cheap effective vaccines?
Why does Russia fight so hard to get them to buy gas and vaccines... I am sure the rest of the world would not only be interested in buying the vaccines but also joint production and cooperation in other areas of mutual interest... why does Russia waste time on these Euro clowns?
Of course if they stopped pandering to the EU and started helping countries in Africa and around the world that also need help but actually want Russian help then of course the EU will complain that Russia is trying to steal their African colonies away from them...
Why does Russia fight so hard to get them to buy gas and vaccines... I am sure the rest of the world would not only be interested in buying the vaccines but also joint production and cooperation in other areas of mutual interest... why does Russia waste time on these Euro clowns?
Of course if they stopped pandering to the EU and started helping countries in Africa and around the world that also need help but actually want Russian help then of course the EU will complain that Russia is trying to steal their African colonies away from them...
Hole likes this post
Kiko- Posts : 3435
Points : 3499
Join date : 2020-11-11
Age : 75
Location : Brasilia
- Post n°374
Re: Russian Medical Development: News
Drug to calm cytokine storm: Life-saving Russian discovery could be key to stopping body’s ‘suicide attack’ in severe Covid cases, 12/10/2021.
A group of Russian scientists have created a drug that may potentially revolutionize the treatment of Covid-19 by defusing the most catastrophic reaction the disease causes in patients, while not destroying their immune response.
The drug, called Leitragin, was developed by the Biomedical Technology Research Center of the Russian Federal Medical and Biology Agency (FMBA), and is currently undergoing clinical trials in Russia. Although its base substance was previously known and used in ulcer treatment medicine by Soviet and Russian doctors, it was the FMBA team that discovered how to apply it for the treatment of severe cases of Covid-19 and, potentially, other deadly diseases that cause life-threatening lung inflammation.
The Russian scientists had tasked themselves with finding a substance that would act as an ‘off switch’ for the chain reaction that, after being triggered by the invading SARS-CoV-2 virus, actually causes potential organ failure and death. This reaction of the immune system, dubbed the “cytokine storm,” has been variously described as our body’s overreaction to the virus or a “suicide attack” against the invading pathogen, and even as an evolutionary mechanism to stop the spread of deadly infections with the death of the host.
Trying to stop this uncontrolled immune response while still preserving the body’s ability to fight the virus without causing more damage is what scientists and medics in intensive care units across the world have been wrestling with during the Covid-19 pandemic. In that regard, Leitragin is being touted as a game-changer, since its novel mechanism acts in a targeted way, and is said to be completely safe for one’s health.
RT interviewed the head of the Russian team of scientists behind Leitragin, and talked to an independent researcher studying cytokine storms, to learn more about the potential of the novel drug.
In search of the deadly trigger
A cytokine storm, also known as hypercytokinemia, is triggered by tiny messenger proteins called cytokines, which are normally our body’s trusted agents in dealing with infections, inflammations and trauma. However, when dealing with some dangerous pathogens such as H1N1, H5N1, the Ebola virus, and SARS-CoV-2, the immune system may decide it’s being overwhelmed by the virus and “go mad.” This can result in massive inflammation and, potentially, septic shock and death, Maxim Skulachev, a leading research associate at the Moscow State University’s (MSU) Physicochemical Biology Research Institute, told RT.
Up until now, a cytokine storm was believed to be caused by an uncontrollable release of dozens of different cytokine types, making it difficult to contain. However, scientists at the FMBA Biomedical Technology Research Center say they might just have got to the very bottom of the issue and pinpointed a single key culprit.
The group, led by the head of the center, Vladislav Karkischenko, published the results of their drug’s pre-clinical trials on mice in the Journal of Immunology Research in late September.
At first, the Russian scientists spent months figuring out their Covid-19 infection model – according to Skulachev, the rodents’ response to the disease doesn’t quite match that of humans even in so-called “humanized” mice. Then, they went through a process of drug screening, and identified a substance defusing what they believe is one particular cytokine triggering the storm.
The cytokine in question is called high mobility group box 1 protein, or HMGB1, Karkischenko told RT. Released en masse by the immune cells during severe Covid-19 cases, it triggers the release of numerous other cytokines, turning it into an “uncontrollable process.”
Previous research hasn’t considered HMGB1 as the “main cytokine,” but it’s so ubiquitous, its numbers could be a thousand times higher during the infection, Karkischenko said, which points to it being responsible for the “final cascade of reactions.”
"We believe this late-phase cytokine [HMGB1] is the chief inflammation agent during the [infection with] SARS-CoV-2"
The FMBA scientists are not alone in their assumptions. The HMGB1 protein has already drawn the attention of researchers around the world, and was named as a potential therapeutic target in treating Covid-19.
Commending the “enormous amount of work” done at the FMBA, MSU’s Skulachev says that a team at his institute has achieved similar results during their own research into cytokine storms. Moreover, he believes the two teams may have independently discovered a universal “evolutionary suicide mechanism” that kills an organism to prevent the spread of severe infections.
“This is an evolutionary mechanism we inherited from our ancestors,” Skulachev said, adding that the evolutionary trait hasn’t caught up with the fact that humanity has developed vaccines and medicines to deal with such diseases.
'Solving unsolvable problem'
Currently, medics do not have many options in their fight against the cytokine storm. They have to either use monoclonal antibodies – highly expensive drugs capable of suppressing a single type of cytokine – or “kill” the immune system completely with steroid anti-inflammatory drugs. Both methods have serious drawbacks.
The FBMA center’s research showed that suppressing the oft-targeted cytokines might not always provide the required effect as the “storm” could continue raging after a brief respite, Karkishenko said. Skulachev, meanwhile, notes that using hormonal steroid drugs could be even more dangerous.
“We cannot live without the immune system. If a person has been suffering from a severe viral infection, one has to be meticulous in choosing a moment for administering the drug. Do it a few hours too early and a virus would kill a person through self-replication,” he said.
In their search for a solution, the FMBA researchers tried an opioid hexapeptide called [D-Ala2]-dynorphin 1-6, and the results turned out to be surprisingly promising. Mortality rates among mice with chemically induced conditions similar to cytokine storms in humans fell by four times, Karkishenko said. Noting that Western scientists seem to be focused on opioids as components of painkiller drugs, he adds that these substances are much more multi-faceted, and can also be harmless.
“In our article, we were able to prove that opioid receptors trigger processes with a massive anti-inflammatory effect while causing no damage to a person,” Karkischenko said.
In June, Leitragin was registered by the Russian health authorities as part of an emergency procedure. At that time, the FMBA said that it was already tested on some 300 volunteers and showed very positive results since none of the patients, who were administered Leitragin, were admitted to intensive care units or died. They also tended to recover several days earlier than those who received “standard” treatment, Karkischenko said. Leitragin has initially been intended for testing on Covid patients with moderate severity of the disease, but some doctors have taken it upon themselves to treat critical patients, he added.
“This drug is designed to solve an unsolvable problem. These patients virtually have no other alternatives,” Skulachev explained, referring to severe cases of Covid.
'Major development'
Despite what Karkischenko says are promising results, the scientists behind Leitragin still have to prove its effectiveness in clinical studies. The center is now working on a large-scale publication that would involve clinical trial results and more information about the drug itself. Russia’s hospitals, meanwhile, are allowed to treat patients with Leitragin as part of a limited use authorization.
If proven effective and safe, though, the drug may be found to have uses far beyond Covid-19 treatment, since it’s designed to deal with the immune system’s reaction and not one specific virus.
“Leitragin is aimed at suppressing inflammation processes,” Karkischenko said, adding that “it is a drug based on an absolutely innovative approach” and can be used to treat “various conditions.” The FMBA center is already working on different drug formulations for Leitragin.
“Some 80% of all critical conditions [in patients] in intensive care units are linked to cytokine storm and potentially to this specific protein causing it,” Skulachev explained, noting that the “potential range of uses for this drug could be extremely wide.”
"It could be a major development".
https://www.rt.com/russia/537205-new-covid-drug-cytokine-storm/
A group of Russian scientists have created a drug that may potentially revolutionize the treatment of Covid-19 by defusing the most catastrophic reaction the disease causes in patients, while not destroying their immune response.
The drug, called Leitragin, was developed by the Biomedical Technology Research Center of the Russian Federal Medical and Biology Agency (FMBA), and is currently undergoing clinical trials in Russia. Although its base substance was previously known and used in ulcer treatment medicine by Soviet and Russian doctors, it was the FMBA team that discovered how to apply it for the treatment of severe cases of Covid-19 and, potentially, other deadly diseases that cause life-threatening lung inflammation.
The Russian scientists had tasked themselves with finding a substance that would act as an ‘off switch’ for the chain reaction that, after being triggered by the invading SARS-CoV-2 virus, actually causes potential organ failure and death. This reaction of the immune system, dubbed the “cytokine storm,” has been variously described as our body’s overreaction to the virus or a “suicide attack” against the invading pathogen, and even as an evolutionary mechanism to stop the spread of deadly infections with the death of the host.
Trying to stop this uncontrolled immune response while still preserving the body’s ability to fight the virus without causing more damage is what scientists and medics in intensive care units across the world have been wrestling with during the Covid-19 pandemic. In that regard, Leitragin is being touted as a game-changer, since its novel mechanism acts in a targeted way, and is said to be completely safe for one’s health.
RT interviewed the head of the Russian team of scientists behind Leitragin, and talked to an independent researcher studying cytokine storms, to learn more about the potential of the novel drug.
In search of the deadly trigger
A cytokine storm, also known as hypercytokinemia, is triggered by tiny messenger proteins called cytokines, which are normally our body’s trusted agents in dealing with infections, inflammations and trauma. However, when dealing with some dangerous pathogens such as H1N1, H5N1, the Ebola virus, and SARS-CoV-2, the immune system may decide it’s being overwhelmed by the virus and “go mad.” This can result in massive inflammation and, potentially, septic shock and death, Maxim Skulachev, a leading research associate at the Moscow State University’s (MSU) Physicochemical Biology Research Institute, told RT.
Up until now, a cytokine storm was believed to be caused by an uncontrollable release of dozens of different cytokine types, making it difficult to contain. However, scientists at the FMBA Biomedical Technology Research Center say they might just have got to the very bottom of the issue and pinpointed a single key culprit.
The group, led by the head of the center, Vladislav Karkischenko, published the results of their drug’s pre-clinical trials on mice in the Journal of Immunology Research in late September.
At first, the Russian scientists spent months figuring out their Covid-19 infection model – according to Skulachev, the rodents’ response to the disease doesn’t quite match that of humans even in so-called “humanized” mice. Then, they went through a process of drug screening, and identified a substance defusing what they believe is one particular cytokine triggering the storm.
The cytokine in question is called high mobility group box 1 protein, or HMGB1, Karkischenko told RT. Released en masse by the immune cells during severe Covid-19 cases, it triggers the release of numerous other cytokines, turning it into an “uncontrollable process.”
Previous research hasn’t considered HMGB1 as the “main cytokine,” but it’s so ubiquitous, its numbers could be a thousand times higher during the infection, Karkischenko said, which points to it being responsible for the “final cascade of reactions.”
"We believe this late-phase cytokine [HMGB1] is the chief inflammation agent during the [infection with] SARS-CoV-2"
The FMBA scientists are not alone in their assumptions. The HMGB1 protein has already drawn the attention of researchers around the world, and was named as a potential therapeutic target in treating Covid-19.
Commending the “enormous amount of work” done at the FMBA, MSU’s Skulachev says that a team at his institute has achieved similar results during their own research into cytokine storms. Moreover, he believes the two teams may have independently discovered a universal “evolutionary suicide mechanism” that kills an organism to prevent the spread of severe infections.
“This is an evolutionary mechanism we inherited from our ancestors,” Skulachev said, adding that the evolutionary trait hasn’t caught up with the fact that humanity has developed vaccines and medicines to deal with such diseases.
'Solving unsolvable problem'
Currently, medics do not have many options in their fight against the cytokine storm. They have to either use monoclonal antibodies – highly expensive drugs capable of suppressing a single type of cytokine – or “kill” the immune system completely with steroid anti-inflammatory drugs. Both methods have serious drawbacks.
The FBMA center’s research showed that suppressing the oft-targeted cytokines might not always provide the required effect as the “storm” could continue raging after a brief respite, Karkishenko said. Skulachev, meanwhile, notes that using hormonal steroid drugs could be even more dangerous.
“We cannot live without the immune system. If a person has been suffering from a severe viral infection, one has to be meticulous in choosing a moment for administering the drug. Do it a few hours too early and a virus would kill a person through self-replication,” he said.
In their search for a solution, the FMBA researchers tried an opioid hexapeptide called [D-Ala2]-dynorphin 1-6, and the results turned out to be surprisingly promising. Mortality rates among mice with chemically induced conditions similar to cytokine storms in humans fell by four times, Karkishenko said. Noting that Western scientists seem to be focused on opioids as components of painkiller drugs, he adds that these substances are much more multi-faceted, and can also be harmless.
“In our article, we were able to prove that opioid receptors trigger processes with a massive anti-inflammatory effect while causing no damage to a person,” Karkischenko said.
In June, Leitragin was registered by the Russian health authorities as part of an emergency procedure. At that time, the FMBA said that it was already tested on some 300 volunteers and showed very positive results since none of the patients, who were administered Leitragin, were admitted to intensive care units or died. They also tended to recover several days earlier than those who received “standard” treatment, Karkischenko said. Leitragin has initially been intended for testing on Covid patients with moderate severity of the disease, but some doctors have taken it upon themselves to treat critical patients, he added.
“This drug is designed to solve an unsolvable problem. These patients virtually have no other alternatives,” Skulachev explained, referring to severe cases of Covid.
'Major development'
Despite what Karkischenko says are promising results, the scientists behind Leitragin still have to prove its effectiveness in clinical studies. The center is now working on a large-scale publication that would involve clinical trial results and more information about the drug itself. Russia’s hospitals, meanwhile, are allowed to treat patients with Leitragin as part of a limited use authorization.
If proven effective and safe, though, the drug may be found to have uses far beyond Covid-19 treatment, since it’s designed to deal with the immune system’s reaction and not one specific virus.
“Leitragin is aimed at suppressing inflammation processes,” Karkischenko said, adding that “it is a drug based on an absolutely innovative approach” and can be used to treat “various conditions.” The FMBA center is already working on different drug formulations for Leitragin.
“Some 80% of all critical conditions [in patients] in intensive care units are linked to cytokine storm and potentially to this specific protein causing it,” Skulachev explained, noting that the “potential range of uses for this drug could be extremely wide.”
"It could be a major development".
https://www.rt.com/russia/537205-new-covid-drug-cytokine-storm/
GarryB and kvs like this post
George1- Posts : 18456
Points : 18955
Join date : 2011-12-22
Location : Greece
- Post n°375
Re: Russian Medical Development: News
Sputnik Light may serve as universal booster for most COVID jabs, says RDIF chief
According to the Gamaleya National Research Center for Epidemiology and Microbiology, the one-shot Sputnik Light jab has shown 70% efficacy against the Delta variant for three months after vaccination
MOSCOW, October 13. /TASS/. Russia’s Sputnik Light jab may become a universal booster for most coronavirus vaccines due to its high efficacy, Russian Direct Investment Fund (RDIF) CEO Kirill Dmitriev told reporters on Wednesday.
"The mRNA vaccines need a booster since their efficacy drops a few months after the injection. We believe that Sputnik Light can act as a universal booster jab for many vaccines, given this jab’s very high effectiveness against the Delta variant. And we will be offering the Sputnik shot as a booster revaccination after other inoculations in order to step up effectiveness," Dmitriev said.
According to the Gamaleya National Research Center for Epidemiology and Microbiology, the one-shot Sputnik Light jab (the first dose of the two-shot Sputnik V jab) has shown 70% efficacy against the Delta variant (the prevalent coronavirus variant in Russia) for three months after vaccination.
The jab has demonstrated an efficacy of over 75% in the over-60 age group. Moreover, Sputnik Light has demonstrated "a superior efficacy than some two-shot vaccines, which have shown a major decline in efficacy against the Delta variant to less than 50% five months after injection," the RDIF said on its website.
Sputnik Light is the first dose of the Sputnik V coronavirus vaccine, which was authorized in Russia on August 11, 2020. To date, Sputnik V has been approved for use in 70 countries with a cumulative population of four billion people. On March 4, the EU regulator announced the start of Sputnik V’s rolling review.
https://tass.com/science/1349289
dino00 likes this post
|
|